With experienced practitioners knowledgeable across a multitude of different therapeutic areas, technologies and approaches, our senior professionals have helped emerging and mid-size companies, venture capital firms, research institutions, academia and nonprofit advocacy groups thrive and grow.
Linnden Communication’s senior practitioners have extensive experience planning and executing strategic communications across the gamut of life science needs to elevate organization’s visibility with influential target audiences, including:
STRATEGIC
COUNSEL
Messaging / positioning, communications plans, crisis management, spokesperson coaching
THOUGHT
LEADERSHIP
Speaking engagements, scientific awareness, awards, opinion pieces, community relations
Media
Relations
Publicity across scientific, trade, and mass media outlets, media training
Investor
Relations
Financing/IPO support, investor decks, disclosure guidance, quarterly releases
content
production
Press releases, website, backgrounders, fact sheets, contributed articles, editorial content
social
media
Full range of integrated multimedia support across channels
Graphics/
Visuals
Branding, logos, website design, presentations, infographics, marketing materials
Linnden Communication’s team of experts has extensive experience leading communications efforts for some of the largest life science organizations, media outlets, PR agencies and academic institutions. Our practitioners have an average of 20+ years of industry experience as communications and PR professionals which we are happy to share with our clients.
- Company launches
- Run-up to IPO
- Venture investment and public financings
- Collaborations and partnerships
- Product launches and updates
- Executive leadership changes and advisory board updates
- Initiation of clinical trials
- Clinical data readouts
- Scientific publications/presentations
- Facility openings/ribbon cuttings
- Trade shows and speaking engagements
- Repositioning
- Crises and issues
Linnden Communication’s seasoned professionals have been on all sides of the table in life science communications efforts, whether in agencies, as reporters being pitched, in-house practitioners working with outside agencies, or academics and non-profits collaborating with industry.
We understand the challenges of small life science organizations and are ready to serve as your affordable, experienced in-house communications team, and for larger companies we can jump in at a minute’s notice to lend a hand to an existing in-house communications team with specific areas of need.
We don’t have junior staff running your program, monthly retainers, or big agency pricing – and timelines – that could slow your growth. Through years of experience, Linnden team members have gained the trust of and developed strong relationships with media, investors and other key constituents in the life science industry. We’re a flexible, dynamic senior team with a strong track record of delivering cost-effective and high value communications solutions.
Axios: Exclusive: Metabolic biotech Junevity doubles seed round to $20M
BBC: The mystery of the human genome’s dark matter
BioCentury: Suppressor tRNAs: Giving genetic medicines a broader reach
BioPharma Dive: Chroma, Nvelop merge to marry genetic medicine ‘cargo’ to delivery
BioWorld: Dewpoint and Chemify partner on molecules targeting condensates in oncology and neurodegeneration
Biospace: Lilly, Haya Ink Potential $1B Drug Discovery Deal to Target Obesity and Metabolic Conditions
Chemical & Engineering News: AI is coming. Is the chemistry world ready?
Endpoints: French biotech Enodia gets €20.7M co-led by Pfizer for protein degrader work
European Biotechnology: Enodia Therapeutics raises €20.7m seed round for targeted protein degradation pipeline
Financial Times: Robots promise to take the grunt work out of laboratory experiments
Forbes: Treating High Cholesterol Could Become A One-And-Done Treatment
Genetic Engineering News: Chroma Medicine, Nvelop Therapeutics Merge as nChroma
Inside Precision Medicine: Atomic AI’s Large Language Model Employs Chemical Mapping Data to Optimize RNA Therapies
The Medicine Maker: Taking on the Genetic Nonsense with tRNAs
Nature: Editor’s Pick: Atomic AI
San Francisco Business Times: Biotech startup looks to challenge the ‘really messy situation’ of aging
Scrip: HAYA Raises $65m To Take First Long Non-Coding RNA Program Into The Clinic
STAT: Life science investors close nearly $6 billion in new funds
Venture Capital Journal: Bioluminescence Ventures Taps Murray as senior partner
Wall Street Journal Pro Venture Capital: Beyond GLP-1: Junevity Seeks Next-Generation Weight-Loss Medication
Wall Street Journal: Lifordi Focuses on Autoimmune Diseases
Award: BioSpace NextGen: Class of 2026
Award: 2025 Emergine Pharma Leaders
Contributed article: How The New Biotech Market Is Redefining Leadership
Contributed article: Junk DNA: How the dark genome is changing RNA therapies
Contributed article: Unlocking the Potential of Transcription Factors
Opinion piece: Rethinking Pharma and Biotech Outsourcing
Podcast: Hitting the Reset Button on Cellular Aging
Podcast: Raphael Townshend: How AI and RNA Tech is Transforming Drug Discovery (Inside Atomic AI)
Speaking engagement: How VCs Evaluate Risk in Early Stage Startups
Speaking engagement: Integrating AI-Driven Drug Discovery to Improve R&D Supply Chain Efficiency
Webinar: Drug Digest: Outsourcing Partnerships Fuel Global Biopharma Discovery and Scale-Up
Webinar: RNA Delivery Reimagined: Innovative Nonviral Strategies Beyond LNPs
Webinar: The Intersection of Chemistry, Robotics, and AI in Drug Discovery

